Martínez Velasco E, Gómez Castillo J J, Fernández Megía M J, González Joga B, Barreda Hernández D, Gómez Roncero M I
Servicio de Farmacia, Hospital Virgen de la Luz, Cuenca.
Farm Hosp. 2007 Mar-Apr;31(2):124-7. doi: 10.1016/s1130-6343(07)75724-0.
To evaluate the efficacy and safety of treatment with rituximab in patients presenting autoimmune thrombocytopenic purpura and haemolytic anaemia.
A check was carried out of the medical records of the patients starting treatment with rituximab for compassionate use in 2004 at doses of 375 mg/m2 per week for 4 weeks. The rate of patients achieving full response in accordance with the best criteria found in the bibliography was assessed. All adverse reactions described in the medical records were gathered.
Six patients with thrombocytopenic purpura were candidates for treatment. Five began treatment, four of them completed treatment, and three of these patients achieved full response. This response was achieved at different times and was sustained for at least six months. Two patients with autoimmune haemolytic anaemia were treated and both achieved full response again at different times and in this case, it was sustained for at least 8 months. One patient suffered mild adverse reactions to treatment.
Rituximab is a new perspective for the treatment of refractory autoimmune cytopenias, and has a good safety profile.
评估利妥昔单抗治疗自身免疫性血小板减少性紫癜和溶血性贫血患者的疗效及安全性。
对2004年开始接受利妥昔单抗同情用药治疗的患者病历进行核查，用药剂量为375mg/m²，每周一次，共4周。根据参考文献中找到的最佳标准评估达到完全缓解的患者比例。收集病历中描述的所有不良反应。
6例血小板减少性紫癜患者符合治疗条件。5例开始治疗，其中4例完成治疗，3例患者达到完全缓解。这种缓解在不同时间实现，并持续至少6个月。2例自身免疫性溶血性贫血患者接受治疗，均在不同时间再次达到完全缓解，且在这种情况下持续至少8个月。1例患者出现轻度治疗不良反应。
利妥昔单抗是治疗难治性自身免疫性血细胞减少症的新方法，且安全性良好。
